This has been exemplified clinically with poly ADP-ribose polymerase inhibitors (PARPi) used to treat cancers with mutations in genes required for homologous recombination – most notably BRCA1 and BRCA2 [3]. This evidence concerns the gene BRCA1 and cancer.